Similarly, the BCL2/Bcl-xL inhibitor ABT-737 associated with Imatinib demonstrated strong synergism to induce cell death of both proliferating and quiescent CD34+/CD38− TKI-insensitive CML cell populations [22,23]. This evidence concerns the gene BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive.